Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal
Cycle Pharmaceuticals wants to acquire Vanda Pharmaceuticals for $8 per share, or $466 million. Cycle focuses on rare neurological conditions.
Eli Lilly’s Alzheimer’s Drug, Donanemab Faces FDA’s Adcomm Vote Next Week On Data, Risk Profile
The FDA's advisory committee will review Eli Lilly's Phase 3 study on donanemab for Alzheimer's disease on June 10. This review assesses the drug's benefit-risk profile based on significant efficacy results in cognition and daily function.
Novavax Stock Soars On FDA COVID-19 Update: Fundamental Rally Or Potential Short Squeeze?
Novavax (NASDAQ: NVAX) stock surges on positive COVID-19 vaccine news, with FDA setting a PDUFA review date for April 2025. High trading volume and strong technical indicators make it a compelling investment opportunity.
FDA Selects Moderna’s Rare Disease Candidate For Accelerated Development Program
Moderna's mRNA-370 has been selected for the FDA's START program to accelerate rare disease therapeutics, targeting a 2024 pivotal study.
What’s Going On With Sagimet Biosciences Stock On Thursday?
Sagimet Biosciences shared promising data from its FASCINATE-2 Phase 2b trial of denifanstat at the EASL Congress.
AbbVie Announces Topline Results From Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine For High Folate Receptor-Alpha Expressing Platinum-Sensitive Ovarian Cancer; PICCOLO Met Its Primary Endpoint With An ORR Of 51.9%; The Median DOR, A Key S…
PICCOLO trial met its primary endpoint of objective response rate (ORR)Data from the study will be presented at a future medical meetingNORTH CHICAGO, Ill., June 6, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced
Novavax Stock Rallies In Pre-Market As Company Plans To Deliver Covid-19 Vaccine By September
The company also mentioned that it anticipates commercial delivery of the protein-based vaccine in the U.S. in September, pending authorization. The
Melt Pharmaceuticals Reports First Patient Dosed In Phase 3 Program Of Its MELT-300, For Needle- And Opioid-Free Sedation In Patients Undergoing Cataract Surgery; Topline Readout Expected In Q4 2024
Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3 program evaluating
Tonix Pharmaceuticals Presents Two Oral Presentations And One Poster Presentation Involving TNX-1500 At The American Transplant Congress 2024
TNX-1500 displays potential as a monotherapy or combination therapy to prevent rejection in organ transplantation in allograft and xenograft animal models Research Directed by Faculty of the Center for
Twist Bioscience Preclinical Data Detailing Discovery Of Antibody Targeting Emerging Checkpoint Inhibitor Published In The Journal PLOS ONE
TB206-001 shown to be a high-affinity, cross-reactive humanized antibody antagonist of A2AR with in vivo tumor suppressing activityTB206-001 available for out-licensingTwist Bioscience Corporation (NASDAQ:TWST), a